- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Variation in Out-of-Pocket Drug Costs in Covered California
Consumers with chronic diseases face challenging trade-offs when choosing health coverage, especially when it comes to out-of-pocket drug costs.
Health plans offered through Covered California in 2014 had a significant variation in prescription drug coverage, particularly for drugs treating medication-reliant chronic conditions. Researchers with the California Healthcare Foundation determined consumers' out-of-pocket costs were affected by this variation and formulary design. Because of specialty tier costs and deductibles. medication-reliant consumers, regardless of their income, faed front-loaded spending at the start of the year, according to the report.
In addition, consumers will medication-reliant chronic conditions, such as bipolar affective disorder and rheumatoid arthritis, experienced higher out-of-pocket costs than those who don't use specialty drugs.
According to the Foundation, Covered California will be taking steps for the 2016 benefit year to addresses these concerns about high out-of-pocket costs for some prescription drugs. Prescription drug formulary placement is the primary source of out-of-pocket cost variation across plans because California standardizes benefit designs.
Read more at the California Healthcare Foundation: http://bit.ly/1Lz76Sx
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
November 1st 2024The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
Read More
